ORIC PHARMACEUTICALS, INC. (ORIC) Operating Margin
- Operating margin · 12 months: Value (m); Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | (m) | Operating income / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -156.14M USD | Operating Income (Loss) |
| Revenue | (m) | |
| Cost of products and services | (m) | |
| Research and development | (m) | Research and Development Expense |
| Selling, general and administration | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-156.14M | (m) | (m) | (m) | (m) | (m) |
| 2026-03-31 | $-149.91M | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | $-143.00M | (m) | (m) | (m) | (m) | (m) |
| 2025-09-30 | $-148.02M | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | $-149.67M | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | $-146.62M | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | $-142.90M | (m) | (m) | (m) | (m) | (m) |
| 2024-09-30 | $-134.75M | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | $-125.12M | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | $-114.09M | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | $-110.78M | (m) | (m) | (m) | (m) | (m) |
| 2023-09-30 | $-101.47M | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | $-98.48M | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | $-94.19M | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | $-91.77M | (m) | (m) | (m) | (m) | (m) |
| 2022-09-30 | $-92.45M | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | $-85.22M | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | $-85.58M | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | $-78.87M | (m) | (m) | (m) | (m) | (m) |
| 2021-09-30 | $-84.35M | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | $-91.49M | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | $-81.56M | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $-74.19M | (m) | (m) | (m) | (m) | (m) |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | $-28.57M | (m) | (m) | (m) | (m) | (m) |
| 2019-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | $-22.37M | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |